AI Engines For more Details: Perplexity Kagi Labs You
Motion Sickness: Diphenidol hydrochloride is commonly used to prevent and treat motion sickness, which can occur during travel by car, boat, airplane, or other modes of transportation. By blocking signals in the brain that trigger nausea and vomiting in response to motion, diphenidol helps alleviate symptoms such as nausea, vomiting, dizziness, and sweating associated with motion sickness.
Vertigo: Diphenidol hydrochloride may also be used in the management of vertigo, a sensation of spinning or dizziness that can be caused by various conditions affecting the inner ear or the balance centers of the brain. By exerting its anticholinergic effects, diphenidol can help reduce the severity and frequency of vertigo episodes and improve overall balance and stability.
Nausea and Vomiting: In addition to motion sickness and vertigo, diphenidol hydrochloride may be prescribed to relieve nausea and vomiting associated with other conditions, such as gastrointestinal infections, chemotherapy, or postoperative recovery. It helps suppress the vomiting reflex and alleviate symptoms, making it easier for individuals to tolerate oral intake and maintain hydration.
Postoperative Nausea and Vomiting (PONV): Diphenidol hydrochloride may be used as part of multimodal therapy to prevent or reduce postoperative nausea and vomiting in individuals undergoing surgery. By blocking signals in the brain that trigger nausea and vomiting in response to anesthesia or surgical stress, diphenidol can help improve postoperative comfort and recovery.
Dizziness: Diphenidol hydrochloride's anticholinergic effects may also be beneficial in reducing dizziness associated with various medical conditions, such as labyrinthitis, Meniere's disease, or vestibular neuritis. It helps stabilize the vestibular system and reduce the perception of dizziness or imbalance.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 0 | 1 | Bacteroides luhongzhouii | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 0 | 1 | Bacteroides faecium | species | Decreases |
| 0 | 1 | Bacteroides caecimuris | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.1 | 2 |
| Allergies | 0.2 | 0.8 | -3 |
| Allergy to milk products | 0.5 | 0.3 | 0.67 |
| Alzheimer's disease | 1 | 0.3 | 2.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.4 | 0.4 | 0 |
| Anorexia Nervosa | 0.1 | 0.3 | -2 |
| Asthma | 0.3 | 0.6 | -1 |
| Atherosclerosis | 0.4 | 0.1 | 3 |
| Atrial fibrillation | 0.3 | 0.3 | 0 |
| Autism | 0.8 | 0.8 | 0 |
| Barrett esophagus cancer | 0.1 | 0.1 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 0.3 | 0.1 | 2 |
| Brain Trauma | 0.3 | -0.3 | |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.1 | 0.1 | |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.3 | 0.4 | -0.33 |
| Cerebral Palsy | 0.4 | 0.3 | 0.33 |
| Chronic Fatigue Syndrome | 0.7 | 0.4 | 0.75 |
| Chronic Kidney Disease | 0.3 | 0.1 | 2 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.1 | 0 |
| Chronic Urticaria (Hives) | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
| Cognitive Function | 0.3 | 0.3 | |
| Colorectal Cancer | 0.8 | 0.3 | 1.67 |
| Constipation | 0.4 | 0.4 | |
| Coronary artery disease | 0.1 | 0.3 | -2 |
| COVID-19 | 0.8 | 0.9 | -0.13 |
| Crohn's Disease | 0.9 | 0.7 | 0.29 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.3 | 0.3 | 0 |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 0.8 | 0.7 | 0.14 |
| Eczema | 0.1 | 0.1 | |
| Endometriosis | 0.3 | 0.1 | 2 |
| Eosinophilic Esophagitis | 0.1 | 0.1 | |
| Epilepsy | 0.5 | 0.6 | -0.2 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.4 | -0.4 | |
| Functional constipation / chronic idiopathic constipation | 0.4 | 0.3 | 0.33 |
| gallstone disease (gsd) | 0.1 | 0.2 | -1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
| Generalized anxiety disorder | 0.5 | 0.4 | 0.25 |
| Gout | 1 | 0.1 | 9 |
| Graves' disease | 0.3 | 0.3 | 0 |
| Gulf War Syndrome | 0.3 | -0.3 | |
| Halitosis | 0.5 | 0.5 | |
| Hashimoto's thyroiditis | 0.5 | 0.4 | 0.25 |
| Heart Failure | 0.5 | 0.2 | 1.5 |
| hemorrhagic stroke | 0.1 | 0.1 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.1 | -0.1 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | -0.2 | |
| hyperglycemia | 0.1 | 0.6 | -5 |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypertension (High Blood Pressure | 0.6 | 0.4 | 0.5 |
| Hypothyroidism | 0.1 | 0.1 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 0.4 | 0.2 | 1 |
| Inflammatory Bowel Disease | 0.7 | 0.8 | -0.14 |
| Insomnia | 0.3 | 0.7 | -1.33 |
| Intelligence | 0.4 | 0.4 | |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 0.8 | 0.8 | 0 |
| ischemic stroke | 0.3 | 0.3 | 0 |
| Liver Cirrhosis | 0.5 | 0.8 | -0.6 |
| Long COVID | 0.5 | 0.6 | -0.2 |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.2 | 0.1 | 1 |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Menopause | 0.1 | -0.1 | |
| Metabolic Syndrome | 0.5 | 0.9 | -0.8 |
| Mood Disorders | 0.9 | 0.6 | 0.5 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.5 | 0.3 | 0.67 |
| Multiple system atrophy (MSA) | 0.3 | 0.1 | 2 |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.6 | -0.5 |
| NonCeliac Gluten Sensitivity | 0.5 | 0.3 | 0.67 |
| Obesity | 0.8 | 0.9 | -0.13 |
| obsessive-compulsive disorder | 0.6 | 0.5 | 0.2 |
| Osteoarthritis | 0.4 | 0.4 | 0 |
| Osteoporosis | 0.3 | 0.5 | -0.67 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 0.7 | 0.4 | 0.75 |
| Polycystic ovary syndrome | 0.5 | 0.5 | 0 |
| primary biliary cholangitis | 0.2 | -0.2 | |
| Primary sclerosing cholangitis | 0.3 | 0.1 | 2 |
| Psoriasis | 0.2 | 0.5 | -1.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.3 | 1.33 |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 0.8 | 0.4 | 1 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.4 | -0.4 | |
| Sleep Apnea | 0.1 | 0.3 | -2 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.5 | 0 |
| Systemic Lupus Erythematosus | 0.3 | 0.1 | 2 |
| Tic Disorder | 0.1 | 0.1 | |
| Tourette syndrome | 0.1 | 0.3 | -2 |
| Type 1 Diabetes | 0.6 | 0.4 | 0.5 |
| Type 2 Diabetes | 0.6 | 0.9 | -0.5 |
| Ulcerative colitis | 0.5 | 0.8 | -0.6 |
| Unhealthy Ageing | 0.6 | 0.1 | 5 |
| Vitiligo | 0.3 | 0.1 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
